All of the following are poor prognostic markers of multiple myeloma, except:
**Core Concept**
Multiple myeloma is a type of blood cancer characterized by the proliferation of malignant plasma cells in the bone marrow. Prognostic markers are crucial in determining the outcome and guiding treatment.
**Why the Correct Answer is Right**
Since the question is incomplete, let's discuss general poor prognostic markers in multiple myeloma, which include high levels of **beta-2 microglobulin**, **albumin** levels (low), **LDH** (lactate dehydrogenase) levels (high), and specific **cytogenetic abnormalities** like deletion of 17p or translocations involving the **IgH** locus.
**Why Each Wrong Option is Incorrect**
**Option A:** Would be incorrect if it mentioned a known poor prognostic factor.
**Option B:** Similarly, if it listed another adverse marker.
**Option C:** If it referred to a factor known to worsen prognosis.
**Option D:** Assuming it's the correct choice due to the question's nature, we can't assess without the options.
**Clinical Pearl / High-Yield Fact**
A key point in multiple myeloma prognosis is the role of **cytogenetics** and **serum beta-2 microglobulin** levels. High-risk cytogenetic features and elevated beta-2 microglobulin are associated with a poorer prognosis.
**Correct Answer:** Not provided due to incomplete question.